

COURSE PROGRAM

SUNDAY, OCTOBER 11, 2015

All day	Arrival and hotel check-in
16:00	Registration and distribution of Course Material, Prima Royale Hotel
19:30	Get-Together, Prima Royale Hotel

MONDAY, OCTOBER 12, 2015

08:30 - 09:15	Opening Session	Auditorium de Botton
---------------	------------------------	----------------------

WELCOME ADDRESS AND INTRODUCTION TO THE COURSE
S.I. Johannessen, Chair, Organizing Committee, Norway
M. Bialer, CEA Chair and Member of the Organizing Committee, Israel
J. Buelow, Vice President of Programs and Research, Epilepsy Foundation, USA
H.S. White, CURE Research Director, USA

INTRODUCTION TO THE COURSE
T. Tomson, Organizing Committee, Sweden

STUDENT INTRODUCTIONS
Each student to present him/herself

09:15 - 10:00	Introductory Lecture	Auditorium de Botton
---------------	-----------------------------	----------------------

Chairpersons: **E. Beghi**, Italy
T. Tomson, Sweden

09:15	DEFINITIONS, CLASSIFICATION AND EPIDEMIOLOGY OF SEIZURES AND EPILEPSY J.H. Cross , UK (for definition/classification) E. Beghi , Italy (for epidemiology) E. Trinka , Austria (for status epilepticus)
09:45	Discussion

MONDAY, OCTOBER 12, 2015 (continued)

10:00 – 12:15 Session I: Auditorium de Botton
THE PHARMACOLOGY OF AEDs

Chairpersons: **S.I. Johannessen**, Norway
C. Johannessen Landmark, Norway

10:00 ANTISEIZURE MEDICINES: MECHANISMS OF ACTION AND RATIONAL
POLYPHARMACY
H.S. White, USA

10:45 Discussion

11:00 *Coffee Break*

11:30 EXPERIMENTAL MODELS FOR THE DISCOVERY AND TESTING OF AED
H.S. White, USA

12:00 Discussion

12:15 - 15:30 Session II: Auditorium de Botton
PHARMACOKINETICS AND THERAPEUTIC DRUG MONITORING

Chairpersons: **H.S. White**, USA
S.I. Johannessen, Norway

12:15 BASIC PRINCIPLES OF PHARMACOKINETICS
M. Bialer, Israel

12:45 Discussion

13:00 *Light Lunch*

14:00 PHARMACOKINETIC VARIABILITY OF AEDS IN SPECIAL PATIENT
POPULATIONS, WITH CLINICAL EXAMPLES
C. Johannessen Landmark, Norway

14:30 Discussion

14:45 IMPLEMENTATION OF THERAPEUTIC DRUG MONITORING IN AED
THERAPY, WITH CLINICAL EXAMPLES
S.I. Johannessen, Norway

15:15 Discussion

15:30 *Coffee Break*

16:00 – 17:00 **POSTER PRESENTATIONS I – see page 20** Auditorium de Botton
5 minutes per poster presenter

17:00 – 17:45 **SELECTION OF DRUGS FOR
INITIAL TREATMENT OF ADULTS** Auditorium de Botton

17:00 SELECTION OF DRUGS FOR INITIAL TREATMENT OF ADULTS
E. Trinko, Austria

17:30 Discussion

19:30 *Dinner*

TUESDAY, OCTOBER 13, 2015

08:00 – 10:30 Session III: Auditorium de Botton
DRUG INTERACTIONS

Chairpersons: **M. Bialer**, Israel
R.H. Levy, USA

08:00 MECHANISMS AND PREDICTIONS OF PHARMACOKINETIC INTERACTIONS
OF AEDS –THEORETICAL ASPECTS
R.H. Levy, USA

08:45 Discussion

09:00 CLINICALLY RELEVANT DRUG INTERACTIONS WITH EXAMPLES
R.H. Levy, USA

09:30 Discussion

09:45 ADVERSE EFFECTS OF ANTIEPILEPTIC (ANTISEIZURE) DRUGS
E. Trink, Austria

10:15 Discussion

10:30 *Coffee Break*

11:00- 12:30 **GUIDED CASES: DRUG INTERACTIONS Auditorium de Botton & Fostel Room
AND SPECIAL PATIENT GROUPS
(IN GROUPS)**

Tutors: **M. Bialer**, Israel, **S.I. Johannessen**, Norway,
C. Johannessen Landmark, Norway, **R.H. Levy**, USA,
T. Tomson, Sweden

12:30 *Light Lunch*

13:30 – 14:30 **POSTER PRESENTATIONS II – see page 21 Auditorium de Botton
5 minutes per poster presenter**

14:30 *Coffee Break*

15:00 - 16:30 **WORKSHOP ON HOW TO INITIATE Auditorium de Botton & Fostel Room
A RESEARCH PROGRAM**

Tutors: **J. Buelow**, USA, **R.H. Levy**, USA, **E. Trink**, Austria, **H.S. White**, USA

16:30 *Late afternoon walking tour (to depart directly after sessions)*

20:00 *Dinner*

WEDNESDAY, OCTOBER 14, 2015

08:00 - 12:30 Session IV: Auditorium de Botton
ASSESSING EFFICACY AND SAFETY (1)

Chairpersons: **E. Perucca**, Italy
T. Tomson, Sweden

08:00 THE MEDICAL TREATMENT OF CHRONIC EPILEPSY
S. Shorvon, UK

08:30 Discussion

08:45 CONTROLLED AND UNCONTROLLED TRIALS IN EPILEPSY
E. Perucca, Italy

09:15 Discussion

09:30 STATUS EPILEPTICUS AND ACUTE REPETITIVE SEIZURES
S. Shorvon, UK

10:00 Discussion

10:15 *Coffee Break*

10:45 TERMINATION OF AED THERAPY IN SEIZURE FREE PATIENTS
E. Trinka, Austria

11:15 Discussion

11:30 SPECIFICITIES OF TRIAL DESIGN FOR CHILDREN
J.H. Cross, UK

12:00 Discussion

12:15 *Light Lunch*

13:15- 14:15 **POSTER PRESENTATIONS III** – see page 22 Auditorium de Botton
5 minutes per poster presenter

WEDNESDAY, OCTOBER 14, 2015 (continued)

14:15 - 18:00 Session V: Auditorium de Botton
ASSESSING EFFICACY AND SAFETY (2)

Chairpersons: **F. Vigevano**, Italy
T. Tomson, Sweden

14:15 CRITICAL INTERPRETATION OF DRUG TRIALS IN EPILEPSY
E. Perucca, Italy

14:45 Discussion

15:00 WHEN TO TREAT - AND WITH WHAT DOSAGE?
T. Tomson, Sweden

15:30 Discussion

15:45 *Coffee Break*

16:15 PREGNANCY AND BREAST-FEEDING
T. Tomson, Sweden

16:45 Discussion

17:00 THE 4 PHASES OF DRUG DEVELOPMENT AND REGULATORY AFFAIRS
M. Bialer, Israel

17:30 Discussion

17:45 Discussion and assignments for the Journal Club

19:30 *Dinner*

THURSDAY, OCTOBER 15, 2015

08:30 – 12:00 Session VI: Auditorium de Botton
ASSESSING EFFICACY AND SAFETY (3)

Chairpersons: **J.H. Cross**, UK,
M. Neufeld, Israel

08:30 SEIZURE AGGRAVATION BY ANTIEPILEPTIC DRUGS
E. Perucca, Italy

09:00 Discussion

09:15 SELECTION OF DRUGS FOR INITIAL TREATMENT OF CHILDREN
J.H Cross, UK

09:45 Discussion

10:00 *Coffee break*

10:30 STATISTICAL PRINCIPLES APPLIED TO DESIGN AND ANALYSIS OF
CLINICAL TRIALS
M. Bialer, Israel and **E. Beghi**, Italy

11:00 Discussion

11:15 META-ANALYSIS: ADVANTAGES AND LIMITATIONS
E. Beghi, Italy

11:45 Discussion

12:00 *Light Lunch*

13:00 – 14:00 **POSTER PRESENTATIONS IV – see page 23** Auditorium de Botton
5 minutes per poster presenter

14:00 –16:45 Session VII: Auditorium de Botton
OPTIMIZING MEDICAL MANAGEMENT (1)

Chairpersons: **F. Vigevano**, Italy
E. Beghi, Italy

14:00 WHAT STRATEGY WHEN THE INITIAL DRUG FAILS
E. Beghi, Italy

14:30 Discussion

14:45 DRIVING INNOVATION IN THERAPIES FOR PEOPLE WITH EPILEPSY:
BENCH TO BEDSIDE TO COMMUNITY
J. Buelow, USA

15:15 Discussion

15:30 *Coffee break*

16:00 SEVERE CHILDHOOD EPILEPSIES
F. Vigevano, Italy

16:30 Discussion

19:30 *Dinner*

POSTER PRESENTATIONS I – MONDAY, OCTOBER 12, 2015 (16:00 – 17:00)

Board No.

1. EFFICACY AND TOLERABILITY OF LAMOTRIGINE IN JUVENILE MYOCLONIC EPILEPSY IN ADULTS: A PROSPECTIVE, UNBLINDED RANDOMIZED CONTROLLED TRIAL
R. Andrade-Machado, V. Frades, A. Goicoechea-Astencio, Colombia
2. GENOME-BASED BIOMARKERS OF EARLY TREATMENT RESPONSE IN NEWLY - DIAGNOSED EPILEPSY
P. Auce, B. Francis, A. Jorgensen, M. J. Brodie, A. G. Marson, G. J. Sills, EpiPGx Consortium, UK
3. DESCRIBING A DIRECT MECHANISM OF ACTION FOR THE MCT KETOGENIC DIET
K. Augustin, P. Chen, M. Walker, S. Heales, R. Williams, UK
4. BONE MINERAL DENSITY IN ADULT PATIENTS TREATED WITH VARIOUS ANTI-EPILEPTIC DRUGS
S. A. Beniczky, J. Viken, N. B. Andersen, Denmark
5. THE ROLE OF TOLL-LIKE RECEPTOR 3 IN EPILEPSY
F. Benninger, A. Gross, I. Steiner, E. Okun, D. Offen, Israel
6. SEC-BUTYL-PROPYLACETAMIDE (SPD) AND VALNOCTAMIDE FOR TREATMENT OF STATUS EPILEPTICUS AND ORGANOPHOSPHATE NEURONAL DAMAGE
D. Bibi, H. Mawasi, T. Shekh-Ahmad, M. Bialer, Israel
7. PHARMACOKINETIC VARIABILITY OF CLOBAZAM AND ITS METABOLITE DESMETHYLCLOBAZAM IN CLINICAL PRACTICE – IMPACT OF COMEDICATION
M. L. Burns, S. I. Johannessen, C. Johannessen Landmark, A. Baftiu, M. Stokke Opdal, Norway
8. LONG-TERM PROGNOSIS OF EPILEPSY: THE PRO-LONG STUDY. A MULTI-CENTER RETROSPECTIVE SURVEY OF PROGNOSTIC PATTERNS IN NEWLY DIAGNOSED PATIENTS
D. Carone, S. Beretta, C. Zanchi, M. Pirovano, C. Trentini, E. Bianchi, E. Beghi, C. Ferrarese, Italy
9. A CAUSE OF STATUS EPILEPTICUS IN TURKEY: ISONIAZIDE INTOXICATION
E. K. Coban, **V. B. Dogan**, A. Dirik, Turkey
10. THERAPY DECISIONS IN COMATOSE PATIENTS WITH SUBTLE CLINICAL SIGNS
B. Florea, Romania
11. CHANGES OF BIOELECTRIC ACTIVITY OF THE BRAIN IN PATIENTS WITH CEREBRAL VENOUS PATHOLOGY IN THE LATE PERIOD OF CLOSED HEAD INJURY
V. Florikian, Ukraine

POSTER PRESENTATIONS II – TUESDAY, OCTOBER 13, 2015 (13:30 – 14:30)

Board No.

12. DRUG-RESISTANT EPILEPSY IN A WELL-DEFINED POPULATION OF NORTHERN ITALY
G. Giussani, V. Canelli, S. Romi, E. Bianchi, C. Franchi, A. Nobili, E. Beghi, Italy
13. CORRELATION BETWEEN THE POLYMORPHIC ALLELES CYP2C9 AND THE CONCENTRATION OF VALPROIC ACID IN THE SERUM IN CHILDBEARING-AGE WOMEN
D. Dmitrenko, **Y. Govorina**, N. Shnayder, A. Myravyova, Russia
14. THE PHENOMENOLOGY OF MAJOR DEPRESSION IN EPILEPSY.
A. Guekht, **M. Grishkina**, K. Pochigaeva, O. Tertishnik, Russia
15. CARDIOTOXIC EFFECTS OF ANTIEPILEPTIC DRUGS
V. Grymailo, Ukraine
16. THE TREATMENT OF MIGRAINE IN WOMEN WITH EPILEPSY
I. Iakubenko, T. Litovchenko, I. Pasiura, L. Shevchenko, Ukraine
17. ARE CLINICAL AED PHASE 3 TRIALS SUITABLE TO COVER DRUG RESISTANT EPILEPSY PATIENTS?
T. Intravooth, B. Steinhoff, C. Kurth, Germany
18. COMPLEX PARTIAL SEIZURES IN 46 YEAR OLD WOMAN
J. Bošnjak, **M. Ivica**, Croatia
19. ICTAL EXTRAPYRAMIDAL MOTOR SIGNS IN TEMPORAL AND FRONTAL LOBE EPILEPSY
G. Kalss, U. Fruehwald, G. Bauer, E. Trinkla, Austria
20. DATA OF MISDIAGNOSES OF TRANSIENT CONDITIONS – STUDY IN GEORGIA
K. Khomeriki, T. Jishkariani, L. Abesadze, S. Kasradze, Georgia
21. DIAGNOSIS AND TREATMENT OF IMMUNE-MEDIATED DRUG RESISTANT EPILEPSY: A CASE REPORT
A. Kiryttopoulos, G. Karafyles, M. Spilioti, V. Kimiskidis, I. Kalevrosoglou, D. Panou, H. Alexopoulos, S. Akrivou, Greece
22. POLYMORPHISM OF CYP2C9 AND CYP2C19 IN CHILDREN WITH EPILEPSY
M. Malenica, **M. Kukuruzović**, Croatia
23. RETENTION TIME IN TREATMENT WITH LACOSAMIDE AS ADJUNCTIVE THERAPY IN PATIENTS WITH PHARMACORESISTANT FOCAL EPILEPSY
C. Luisi, A. La Neve, G. Pontrelli, T. Francavilla, G. Boero, M. Giovanna Amoroso, S. Internò, N. Pietrafusa, N. Amoroso, V. Durante, E. Beghi

POSTER PRESENTATIONS III - WEDNESDAY, OCTOBER 14, 2015 (13:15 – 14:15)

Board No.

1. THE ROLE OF ALTERED FUNCTION AND EXPRESSION OF UPTAKE TRANSPORTERS AT THE BLOOD-BRAIN BARRIER IN PHARMACORESISTANCE AND ADVERSE DRUG EFFECTS
A. Mann, D. Ekstein, T. Ben Hur, S. Eyal, Israel
2. SCN1A POLYMORPHISM AND EFFICACY OF LAMOTRIGINE IN PATIENTS WITH EPILEPSY
I. Markovic, N. Bozina, D. Sporis, I. Susak, S. Basic, Croatia
3. OPTICAL IMAGING AS A TOOL FOR EVALUATING THE EFFECTS OF ANTIEPILEPTIC DRUGS ON THE PLACENTA IN VIVO
M. Meir, A. Bishara, E. Portnoy, M. Shmuel, S. Eyal, Israel
4. "REVERSIBLE BRAIN LESIONS" - CASE REPORT
J. Molad, A. Gadoth, M. Neufeld, Israel
5. OCCURRENCE AND LATERALIZING VALUE OF "RARE" PERI-ICTAL VEGETATIVE SYMPTOMS IN TEMPORAL LOBE EPILEPSY
K. Musilová, R. Kuba, M. Brazdil, I. Tyrlikova, I. Rektor, Czech Republic
6. PREVALENCE AND CORRELATES OF SUICIDALITY AMONG ADULT OUTPATIENTS WITH EPILEPSY AT A PSYCHIATRIC HOSPITAL
S. Obasan, E. Somoye, T. Adebawale, Nigeria
7. RISK FACTORS FOR EPILEPSY AMONG NIGERIA AFRICANS
O. Ogunrin, Y. O. Obiabo, **Y. Obiabo**, E. Obehighe, Nigeria
8. DECREASED PROTEIN EXPRESSION OF TUMOR NECROSIS FACTOR RECEPTOR 2 (TNFR2) IN THE HIPPOCAMPUS DURING ACUTE SEIZURES IN A NOVEL MOUSE MODEL OF VIRAL-INDUCED TEMPORAL LOBE EPILEPSY
D. C. Patel, E. J. Dahle, P. M. Billingsley, R.S. Fujinami, H. S. White, K. S. Wilcox, USA

POSTER PRESENTATIONS IV - THURSDAY, OCTOBER 15, 2015 (13:00 -14:00)

Board No.

9. ABCB1 GENE VARIANTS AS PREDICTORS OF MULTIDRUG-RESISTANT EPILEPSY IN CROATIAN POPULATION
S. Basic, **N. Pejanovic Skobic**, Bosnia and Herzegovina
10. COGNITIVE OUTCOMES, DEPRESSION AND ANXIETY IN PATIENTS WITH TRAUMATIC BRAIN INJURY
A. Guekht, V. Krylov, N. Gulyaeva, E. Gusev, I. Kaimovsky, I. Trifonov, A. Talypov, S. Asratyan, A. Yakovlev, A. Lebedeba, **K. Pochigaeva**, W. Allen Hauser, Russia
11. EXPERIENCE WITH LACOSAMIDE IN TREATING FOCAL EPILEPSY PATIENTS IN ROMANIA: EFFICACY, SAFETY AND TIME TO REACH RESPONSE
I. Mindruta, **I. Popa**, O. A. Bajenaru, C. Panea, Romania
12. ETHOSUXIMIDE - FORGOTTEN MEDICINE?
J. Radić Nišević, I. Prpić, Croatia
13. NEW MUTATION IN GRIN1 GENE EXPRESSED AS NEONATAL-ONSET DRUG RESISTANT EPILEPSY ASSOCIATED WITH MALFORMATION OF CORTICAL DEVELOPMENT.
L. Shemer-Meiri, E. Banne, V. Meiner & N. Zelnik, Haifa
14. DRAVET SYNDROME- A CASE REPORT
E. Shpritova, Macedonia
15. EPILEPSY AND SUICIDE: THE IMPORTANCE OF FOLLOW UP
L. Stragapede, G. Furlanis, M. Belluzzo, F. Monti, Italy
16. POSITIVE EFFECT OF CLONAZEPAM IN A BOY WITH MYOCLONIC ASTATIC EPILEPSY (DOOSE SYNDROME)
M. Taghiyeva, Ş.İ Mahalov, Z.M. Aliyev Azerbaijan
17. EPILEPSY IN SHUNT-TREATED CONGENITAL HYDROCEPHALUS: A CASE REPORT
G. Tavchioska, Macedonia

POSTER PRESENTATIONS V - FRIDAY, OCTOBER 16, 2015 (12:00 -13:00)

Board No.

18. NOVEL POSSIBLE MECHANISM THROUGH WHICH ANTIEPILEPTIC DRUGS AFFECT FETAL DEVELOPMENT
N. Tetro, D. Wohl, I. Eisenberg, S. Yagel, T. Imbar, M. Shmuel, S. Eyal, Israel
19. HEADACHE AMONG PATIENTS WITH EPILEPSY: SURVEY OF PRELIMINARY RESULTS
E. Togonidze, S. Kasradze, G. Lomidze, Georgia
20. ETIOLOGY OF CONVULSIVE AND NONCONVULSIVE SEIZURES IN PATIENTS WITH SEVERE TBIV. Krylov, A. Talypov, **I. Trifonov**, Russia
21. PSYCHIATRIC SYMPTOMS AS EARLY AND SOLE MANIFESTATION HERALDING AUTOIMMUNE EPILEPSY. REPORT OF 11 PATIENTS WITH FOCUS ON IMMUNOTHERAPY RESPONSE
A. Vogrig, M. Ferlisi, T. Zanoni, G. Pauletto, L. G. Bongiovanni, P. Manganotti, G. Moretto, S. Monaco
22. THE ROLE OF ENDOTHELIN RECEPTORS IN NEUROCHEMICAL CHANGES IN THE ENDOTHELIN-1 MODEL OF FOCAL CEREBRAL ISCHEMIA IN IMMATURE RATS
K. Vondráková, K. Syslová, M. Mikoška, P. Kačer, H. Kubová , K. Vales, J. Burchfiel, G. Tsenov
23. EFFECTS OF AMBIENT NEUROMODULATORS IN CEREBROSPINAL FLUID ON NEURONAL ACTIVITY IN THE HIPPOCAMPUS
Bjorefeldt, **P. Wasling**, U. Andreasson, E. Hanse, Sweden
24. PHARMACOKINETICS OF NEWER GENERATION ANTIEPILEPTIC DRUGS IN WOMEN WITH EPILEPSY
P. Wong, J. Bainbridge, A. Shrestha, United States
25. NEUROPSYCHOLOGICAL TESTING IN EPILEPTIC PATIENTS WITH MONOTHERAPY VS POLYOTHERAPY
S. Carrasco, N. Giraldo, L. Burriel, J. Galán, **M. Gudín**, J. Vaamonde, Spain
26. AN EVALUATION OF EPILEPSY AND STIGMA IN TURKISH POPULATION
Z. Yildiriim, D. H. Ertem, A. C. Dirican, Y. Altunkaynak, S. Baybas, Turkey